journal
MENU ▼
Read by QxMD icon Read
search

Journal of Ocular Pharmacology and Therapeutics

journal
https://www.readbyqxmd.com/read/28514197/change-of-serum-igg4-in-patients-with-ocular-adnexal-marginal-zone-b-cell-lymphoma-associated-with-igg4-related-ophthalmic-disease-after-treatment
#1
Yuan-Hung Wu, Lei-Chi Wang, Sang-Hue Yen, Wei-Kuang Yu, Shu-Ching Kao, Hui-Chuan Kau, Chieh-Chih Tsai, Catherine Jui-Ling Liu
PURPOSE: To investigate the change of serum IgG4 concentrations correlated with clinical evolution in patients with ocular adnexal marginal zone B cell lymphoma associated with IgG4-related ophthalmic disease (IgG4-ROD). METHODS: Three consecutive patients with histopathologically confirmed ocular adnexal marginal zone B cell lymphoma associated with IgG4-ROD were evaluated. Two patients received radiotherapy and 1 patient received steroid therapy. Treatment outcome was evaluated by clinical symptoms, radiologic examination, and change of serum IgG4 level in these patients...
May 17, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28445077/effect-of-epiretinal-membranes-on-antivascular-endothelial-growth-factor-treatment-for-neovascular-age-related-macular-degeneration
#2
Han Joo Cho, Jae Min Kim, Hyoung Seok Kim, Dong Won Lee, Chul Gu Kim, Jong Woo Kim
PURPOSE: To evaluate the effect of epiretinal membranes (ERMs), detected with spectral-domain optical coherence tomography (SD-OCT), on the outcome of antivascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD). METHODS: A total of 434 eyes with treatment-naive nAMD were retrospectively included and analyzed. All patients were administered an initial series of 3 monthly loading injections of ranibizumab or aflibercept, followed by further injections as required...
April 26, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28441083/eyes-on-new-product-development
#3
Gary D Novack
No abstract text is available yet for this article.
April 25, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28441076/a-novel-neuroprotective-small-molecule-for-glial-cell-derived-neurotrophic-factor-induction-and-photoreceptor-rescue
#4
Petr Baranov, Hong Lin, Kathryn McCabe, David Gale, Shenshen Cai, Burke Lieppman, Dwight Morrow, Phoebe Lei, Justin Liao, Michael Young
PURPOSE: Degenerative diseases of the retina, such as retinitis pigmentosa and age-related macular degeneration, are characterized by the irreversible loss of photoreceptors. Several growth factors, including glial cell derived neurotrophic factor (GDNF), have been shown to rescue retinal neurons. An alternative strategy to direct GDNF administration is its induction in host retina by small molecules. Here we studied the ability of a novel small molecule GSK812 to induce GDNF in vitro/in vivo and rescue photoreceptors...
April 25, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28441068/a-controlled-randomized-double-blind-study-to-evaluate-the-safety-and-efficacy-of-chitosan-n-acetylcysteine-for-the-treatment-of-dry-eye-syndrome
#5
Doreen Schmidl, René Werkmeister, Semira Kaya, Angelika Unterhuber, Katarzyna J Witkowska, Renate Baumgartner, Sonja Höller, Maria O'Rourke, Ward Peterson, Annika Wolter, Martin Prinz, Leopold Schmetterer, Gerhard Garhöfer
PURPOSE: This study was designed to evaluate the effect of chitosan-N-acetylcysteine (C-NAC) eye drops on tear film thickness (TFT) in patients with dry eye syndrome (DES). METHODS: This was a controlled, randomized, double-blind clinical investigation with patients assigned to 2 cohorts. In Cohort I, 21 patients were randomized to receive 1 instillation of C-NAC eye drops in 1 eye and placebo (normal saline solution) in the contralateral eye. In Cohort II, 17 patients were randomized to receive C-NAC eye drops once (QD) or twice (BID) daily for 5 days...
April 25, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28422545/response-to-aslankurt-et-al-re-safety-profile-of-stromal-hydration-of-clear-corneal-incisions-with-cefuroxime-in-the-mouse-model
#6
Mariya Moosajee, Veronica Ferguson
No abstract text is available yet for this article.
April 19, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28414592/understanding-the-presence-and-roles-of-ap4a-diadenosine-tetraphosphate-in-the-eye
#7
Almudena Crooke, Ana Guzman-Aranguez, Gonzalo Carracedo, Maria J Perez de Lara, Jesus Pintor
Diadenosine tetraphosphate abbreviated Ap4A is a naturally occurring dinucleotide, which is present in most of the ocular fluids. Due to its intrinsic resistance to enzyme degradation compared to mononucleotides, this molecule can exhibit profound actions on ocular tissues, including the ocular surface, ciliary body, trabecular meshwork, and probably the retina. The actions of Ap4A are mostly carried out by P2Y2 receptors, but the participation of P2X2 and P2Y6 in processes such as the regulation of intraocular pressure (IOP), together with the P2Y2, is pivotal...
April 17, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28402720/insulin-like-growth-factor-binding-protein-related-protein-1-inhibit-retinal-neovascularization-in-the-mouse-model-of-oxygen-induced-retinopathy
#8
Ping Zhang, Hong Wang, Hui Cao, Xun Xu, Tao Sun
PURPOSE: To explore the inhibitory effect of insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) on retinal angiogenesis and its underlying molecular mechanisms in the mouse model of oxygen-induced retinopathy (OIR). METHODS: C57BL/6J mice were classified into three groups as control group, OIR nonintervention group, and OIR intervention group. Postnatal day 12 (P12) mice in OIR intervention group were received recombinant mouse IGFBP-rP1 (50, 100, and 200 ng/mL) intravitreal injection...
April 12, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28384009/incidence-and-timing-of-the-first-recurrence-in-neovascular-age-related-macular-degeneration-comparison-between-ranibizumab-and-aflibercept
#9
Jae Hui Kim, Young Suk Chang, Dong Won Lee, Chul Gu Kim, Jong Woo Kim
PURPOSE: To compare the incidence and timing of first recurrence between patients who were treated with ranibizumab and aflibercept in neovascular age-related macular degeneration (AMD). METHODS: This retrospective study included 120 patients who received the diagnosis of treatment-naive typical neovascular AMD or polypoidal choroidal vasculopathy (PCV) and were treated using either ranibizumab (n = 73) or aflibercept (n = 47). Recurrence within 10 months of the third injection was compared between the 2 treatment groups...
April 6, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375792/safety-and-efficacy-of-cortisol-phosphate-in-hyaluronic-acid-vehicle-in-the-treatment-of-dry-eye-in-sjogren-syndrome
#10
Maurizio Rolando, Aldo Vagge
PURPOSE: Evaluation of 0.3% cortisol phosphate eye drops in hyaluronic acid vehicle in the treatment of dry eye in Sjogren Syndrome. METHODS: This prospective, single-center, masked (single blind), randomized controlled study included 40 female patients divided into 2 groups, group 1 treated with Idracemi, 0.3% cortisol phosphate eye drops twice a day, and group 2 treated with Cortivis, 0.3% cortisol phosphate in hyaluronic acid vehicle, with the same posology. Screening (day -7), randomization (day 0), follow-up (day 7), and termination (day 28) visits were conducted...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375791/intravitreal-dexamethasone-implant-for-treatment-of-serous-macular-detachment-in-central-retinal-vein-occlusion
#11
Ahmet Elbay, Hakan Ozdemir, Arif Koytak, Arif Melikov
PURPOSE: To evaluate the effect of intravitreal dexamethasone implant (Ozurdex) treatment on serous macular detachment (SMD) in patients with nonischemic central retinal vein occlusion (CRVO). METHODS: Retrospective, interventional, noncomparative case series was conducted. Twenty-four eyes of 24 patients with macular edema (ME) and SMD secondary to nonischemic CRVO made up the study population. Patients who had received intravitreal triamcinolone and/or antivascular endothelial growth factor treatment and/or had undergone retinal photocoagulation were excluded from the study...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375790/the-effect-of-immunologically-safe-plasma-rich-in-growth-factor-eye-drops-in-patients-with-sj%C3%A3-gren-syndrome
#12
Ronald Mauricio Sanchez-Avila, Jesus Merayo-Lloves, Ana Cristina Riestra, Eduardo Anitua, Francisco Muruzabal, Gorka Orive, Luis Fernández-Vega
PURPOSE: The objective was to provide preliminary information about the efficacy and safety of immunologically safe plasma rich in growth factor (immunosafe PRGF) eye drops in the treatment of moderate to severe dry eye in patients with primary and secondary Sjögren's syndrome (SS) and to analyze the influence of several variables on treatment outcomes. METHODS: This retrospective study included patients with SS. All patients were treated with previously immunosafe PRGF eye drops to reduce the immunologic component contents...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375789/the-effect-of-tear-supplementation-with-0-15-preservative-free-zinc-hyaluronate-on-ocular-surface-sensations-in-patients-with-dry-eye
#13
Kristóf Perényi, Lóránt Dienes, Anna Kornafeld, Balázs Kovács, Huba J Kiss, Zsuzsanna Szepessy, Zoltán Z Nagy, Árpád Barsi, M Carmen Acosta, Juana Gallar, Illés Kovács
PURPOSE: To evaluate the effect of tear supplementation with preservative free 0.15% zinc-hyaluronate on ocular surface sensations and corneal sensitivity in dry eye patients. METHODS: Ocular surface sensations were assessed using the ocular surface disease index (OSDI) questionnaire and by recording ocular sensations during forced blinking in parallel with noninvasive tear film breakup time measurement in 20 eyes of 20 dry eye patients. Corneal sensitivity thresholds to selective stimulation of corneal mechano-, thermal- and chemical receptors were measured using the Belmonte gas esthesiometer...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375788/real-world-experience-with-half-time-versus-half-dose-photodynamic-therapy-in-chronic-central-serous-chorioretinopathy
#14
Shu-Yen Peng, Chi-Chun Lai, Nan-Kai Wang, Wei-Chi Wu, Yih-Shiou Hwang, Kuan-Jen Chen, Lee-Jen Chen, Shawn Tsai, Wei-Chun Chan, Laura Liu, Ling Yeung
PURPOSE: To evaluate the real-world experience with half-time photodynamic therapy (PDT) versus half-dose PDT for chronic central serous chorioretinopathy (CSC). METHODS: This multicenter retrospective study enrolled patients who received half-time PDT (with irradiation time shortened to 42 s) or half-dose PDT (with the dosage of verteporfin reduced to 3 mg/m(2)) for chronic CSC and who were followed up for ≧12 months. The success rate, central subfield retinal thickness (CST), and best-corrected visual acuity (BCVA) were documented in each group of patients...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28346860/comparison-of-short-term-effects-of-diquafosol-and-rebamipide-on-mucin-5ac-level-on-the-rabbit-ocular-surface
#15
Yuichi Hori, Tomofumi Kageyama, Asuka Sakamoto, Tomoaki Shiba, Masatsugu Nakamura, Takatoshi Maeno
PURPOSE: To investigate the short-term effects of 2 new secretagogue eye drops for dry eye, 3% diquafosol tetrasodium ophthalmic solution (diquafosol) and 2% rebamipide ophthalmic suspension (rebamipide), on the concentration of mucin 5AC (MUC5AC) in rabbit tear fluid and conjunctival goblet cells. METHODS: One dose of artificial tears, diquafosol or rebamipide, was instilled into 8 eyes of Japanese white rabbits. MUC5AC concentration in the tear fluid was examined using the enzyme-linked immunosorbent assay 15 min after instillation and compared with 8 untreated controls...
March 27, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28338404/effect-of-histone-deacetylase-inhibitor-butyroyloxymethyl-diethyl-phosphate-an-7-on-corneal-neovascularization-in-a-mouse-model
#16
Michal Schaap-Fogler, Irit Bahar, Ada Rephaeli, Mor Dahbash, Abraham Nudelman, Eitan Livny, Tilda Barliya, Yael Nisgav, Tami Livnat
PURPOSE: To examine whether butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, inhibits chemically induced corneal neovascularization (NV) in mice. METHODS: Corneal NV was induced in the right eye of male C57BL mice by application of a mixture of 75% silver nitrate and 25% potassium nitrate to the corneal center. Immediately thereafter, the mice were randomized into 2 groups, receiving an intraperitoneal injection of AN-7 or saline, which served as control...
March 24, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28333572/new-insights-on-complement-inhibitor-cd59-in-mouse-laser-induced-choroidal-neovascularization-mislocalization-after-injury-and-targeted-delivery-for-protein-replacement
#17
Gloriane Schnabolk, Mee Keong Beon, Stephen Tomlinson, Bärbel Rohrer
PURPOSE: The membrane attack complex (MAC) in choriocapillaris (CC) and retinal pigment epithelium (RPE) increase with age and disease (age-related macular degeneration). MAC assembly can be inhibited by CD59, a membrane-bound regulator. Here we further investigated the role of CD59 in murine choroidal neovascularization (CNV), a model involving both CC and RPE, and tested whether CR2-CD59, a soluble targeted form of CD59, provides protection. METHODS: Laser-induced CNV was generated in wild type and CD59a-deficient mice (CD59(-/-))...
March 23, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28300477/evaluation-of-intracameral-pentablock-copolymer-thermosensitive-gel-for-sustained-drug-delivery-to-the-anterior-chamber-of-the-eye
#18
Elizabeth Schaefer, Sara M Smith, Jacklyn Salmon, Santhi Abbaraju, Rasidul Amin, Sidney Weiss, Ulrich Grau, Poonam Velagaleti, Brian Gilger
PURPOSE: To investigate PTSgels (Pentablock copolymers) as an injectable formulation technology for sustained ocular drug delivery. Drug release profile, tolerability, and polymer degradation for one of the thermosensitive, biodegradable, and biocompatible compositions were investigated through intracameral (IC) injection in rabbits. METHODS: New Zealand White rabbit eyes were injected IC (50 μL) with 100 μg near-infrared-immunoglobulin G (NIR-IgG) in balanced salt solution (BSS) or 20% PTSgel; or with PTSgel or BSS alone...
March 16, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28263663/re-safety-profile-of-stromal-hydration-of-clear-corneal-incisions-with-cefuroxime-in-the-mouse-model-by-moosajee-et-al-j-ocul-pharmacol-ther-32-469-475-2016
#19
Murat Aslankurt, İnayet Andı, Osman Çekiç
No abstract text is available yet for this article.
March 6, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28437176/echinocandins-in-ocular-therapeutics
#20
Akash Patil, Soumyajit Majumdar
Fungal infections of the eye, especially fungal keratitis and endophthalmitis, are major causes of concern and if left untreated could lead to vision loss. Currently, natamycin (polyene antifungal) is the only commercially available topical agent used for the treatment of ocular fungal infections. The other antifungals, belonging to the polyene and azole classes, are used off-label in treating ocular infections and are administered topically, orally, intraocularly, or systemically. Even though their use through the different routes of administration has shown favorable outcomes, challenges such as poor ocular penetration, low bioavailability, ocular toxicity, and systemic side effects limit their utility...
February 24, 2017: Journal of Ocular Pharmacology and Therapeutics
journal
journal
32321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"